Carvotroline

Carvotroline
Clinical data
Other namesWY-47791; WY47791; Wy-47791
Routes of
administration		Unknown[1]
Drug classDopamine D2 receptor antagonist; Serotonin 5-HT2A receptor antagonist
ATC code
  • None
Identifiers
  • 8-fluoro-2-(2-pyridin-4-ylethyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H18FN3
Molar mass295.361 g·mol−1
3D model (JSmol)
  • C1CN(CC2=C1NC3=C2C=C(C=C3)F)CCC4=CC=NC=C4
  • InChI=1S/C18H18FN3/c19-14-1-2-17-15(11-14)16-12-22(10-6-18(16)21-17)9-5-13-3-7-20-8-4-13/h1-4,7-8,11,21H,5-6,9-10,12H2
  • Key:PMXOASNGMJAYTN-UHFFFAOYSA-N

Carvotroline (INNTooltip International Nonproprietary Name; developmental code name WY-47791) is a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist which was under development as a potential antipsychotic but was never marketed.[1][2][3][4] It showed modest or moderate affinity for the dopamine D2 and serotonin 5-HT2 receptors and produced antipsychotic-like effects in animals.[5][3][4] The drug was being developed by Wyeth.[1] It reached phase 1 clinical trials prior to the discontinuation of its development.[1][6] Carvotroline was first described in the scientific literature by 1991.[7]

See also

References

  1. ^ a b c d "Carvotroline". AdisInsight. 29 September 2011. Retrieved 12 April 2026.
  2. ^ "Delving into the Latest Updates on Carvotroline with Synapse". Synapse. 28 February 2026. Retrieved 12 April 2026.
  3. ^ a b Abou-Gharbia M (January 2009). "Discovery of innovative small molecule therapeutics". Journal of Medicinal Chemistry. 52 (1): 2–9. doi:10.1021/jm8012823. PMID 19072120.
  4. ^ a b Abou-Gharbia M, Andree TH, Marquis KL, Moyer JA, Haskins JT, Muth E (1992). "WY-47,791 HCl: Preclinical Profile of a Novel Potential Antipsychotic Agent". Clinical Neuropharmacology. 15 24B. doi:10.1097/00002826-199202001-00045. ISSN 0362-5664.
  5. ^ Wise LD, Heffner TG (1992). "Chapter 6. Antipsychotics". Annual Reports in Medicinal Chemistry. Vol. 27. Elsevier. pp. 49–57. doi:10.1016/s0065-7743(08)60404-2. ISBN 978-0-12-040527-5.
  6. ^ Fabre L, Leventer S, Goodman L, Welch M, Baker A (1992). "Ascending Single-Dose Safety and Tolerance of WY-47,791 HCl, a Novel Potential Antipsychotic". Clinical Neuropharmacology. 15 198B. doi:10.1097/00002826-199202001-00381. ISSN 0362-5664.
  7. ^ Abou-Gharbia M, Marquis K, Andree T (1991). "WY-47,791. Antipsychotic". Drugs Future. 16 (11): 1008–1013. doi:10.1358/dof.1991.016.11.154510.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.